U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: ~~August~~January 17, ~~2013~~2015

ISA INTERNATIONALE INC.

(Exact name of registrant as specified in its charter)

Delaware 001-16423 41-1925647

(State of Incorporation) (Commission File Number) (IRS Employer ID. No.)

2564 Rice Street, St. Paul, MN 55113

(Mailing address of principal executive offices) (Zip Code)

(Registrant's telephone number, including area code: (651-484-9850)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[] Written communications pursuant to Rule 425 under the Securities Act

(17CFR230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act

(17CFR240.14A-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Section 1 Business and Operations

Item 1.01 Entry into Material Definitive Agreements:

On ~~July~~December 2831, ~~2013~~2014, ISA Financial Services, Inc. (The “Buyer”)(ISAF), a presently owned 100% unconsolidated investment subsidiary of ISA Internationale, (ISAT), a Business Development Company focused on recruiting, mentoring, coaching, and enhancing investment opportunities for ~~companies~~healthcare inand ~~the~~technology ~~process~~based ~~of going public~~companies, entered into a ~~Financing~~Stock ~~and~~Purchase ~~Conditional~~Agreement ~~Registration~~ Agreement (The “Agreement”) with ~~Cancer~~Doubletree ~~Screening~~Ranch ~~Centers~~Limited ~~(The~~Partnership, an Alaska limited partnership, (“~~Company~~Seller”), awherein ~~corporation~~ISAF ~~under~~ (the ~~state~~“Buyer”) ~~laws~~acquires 100% of ~~Delaware~~the ~~focused~~issued onand ~~establishing~~outstanding ~~cancer~~common ~~screening~~shares ~~centers~~of ~~that~~National ~~offer~~Acceptance, ~~genomic~~a ~~sequencing~~Minnesota Corporation, ~~medical~~engaged ~~testing~~in various investments in equity and bond investments and other real estate activities. National Acceptance Corporation receives 4,500,000 ascommon ~~well~~shares asof ~~coronary~~the ~~artery~~subsidiary ~~MRI~~common stock authorized to be issued. The Company receives an investment in ~~the~~a ~~New~~Company ~~York~~whose assets approximating in excess of $4,500,000 and ~~New~~liabilities ~~Jersey~~totaling ~~area~~approximately $2,000,000.

The ISAF Company iswill ~~seeking~~have tothe ~~raise~~books ~~funds~~and ~~through~~records ~~debt, equity, or a combination~~ of the ~~above~~acquired ~~(Financing~~Company ~~Transaction)~~subject into ~~the~~a ~~amount~~certified ofaudit ~~approximately~~and ~~$7,000,000~~the ~~with~~results ~~further~~filed ~~Financing~~accordingly ~~Transactions~~within to60-70 ~~follow~~days.

The Agreement states that The Company shall remit on the date hereof, a $15,000 non-refundable amount payable in cash to ISAT, and $15,000 non-refundable payment to be made every 30 hereafter for the next 90 days. If during the term of the engagement The Company consummates a Financing Transaction with the assistance of ISAT, or during the 2 years following the termination of the engagement, The Company will compensate ISAT in the amount of 7% of the consideration received.

A copy of this agreement is attached as an exhibit to this 8-K filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ISA INTERNATIONALE INC.

/s/ Bernard L. Brodkorb

By: Bernard L. Brodkorb

President, Chief Executive Officer and Chief Financial Officer

Date: ~~August~~January 18, ~~2013~~2015

Filing Compare · ISA INTERNATIONALE INC